Larimar Therapeutics, Inc. Common Stock
Symbol: LRMR (NASDAQ)
3.98
▲ (2.71%) 0.105
Company Description:
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Key Stats
- Today's Open: $3.9
- Today's High: $4.215
- Today's Low: $3.84
- Today's Volume: 2.01M
- Yesterday Close: $3.87
- Yesterday High: $3.97
- Yesterday Low: $3.78
- Yesterday Volume: 857.04K
- Last Min Volume: 500
- Last Min High: $3.975
- Last Min Low: $3.975
- Last Min VWAP: $3.975
Company Profile
- Name: Larimar Therapeutics, Inc. Common Stock
- Website: https://www.larimartx.com
- Listed Date: 2020-05-29
- Location: BALA CYNWYD, PA
- Market Status: Active
- CIK Number: 0001374690
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $336.37M
- Round Lot: 100
- Outstanding Shares: 85.59M
- Asset Type: CS
RECENT FILINGS FOR LRMR
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-29 | SCHEDULE 13G | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 8-K | View |
| 2025-08-04 | 4 | View |
| 2025-07-31 | SCHEDULE 13D/A | View |
| 2025-07-31 | 8-K | View |
| 2025-07-31 | 424B5 | View |
| 2025-07-29 | 8-K | View |
| 2025-07-29 | 424B5 | View |
| 2025-06-23 | 8-K | View |
| 2025-06-23 | 8-K | View |
| 2025-06-17 | SCHEDULE 13G | View |
| 2025-05-15 | 4 | View |
| 2025-05-14 | 4 | View |
| 2025-05-14 | 4 | View |
| 2025-05-14 | 4 | View |
| 2025-05-14 | 4 | View |
| 2025-05-14 | 4 | View |
| 2025-05-14 | SCHEDULE 13G/A | View |
Latest News on LRMR